Global agreement signed

Article

Bausch + Lomb have signed a global agreement for the rights to distribute Leica's ophthalmic surgical microscopes.

Bausch + Lomb have signed a global agreement for the rights to distribute Leica's ophthalmic surgical microscopes.

Leica's ophthalmic portfolio will be available to B + L, ranging from routine cataract microscopes to high-end retinal systems and including the Leica M822 for cataract procedures which combines LED and halogen lighting for a stable red reflex.

Executive vice president and president of Bausch + Lomb, John Barr, stated, "We are happy to announce the partnership of two leading companies in the field of eye surgery. Bausch + Lomb is a perfect partner for companies, such as Leica Microsystems, looking to broaden their market reach through a powerful worldwide commercial infrastructure."

"Leica Microsystems is a trusted, established brand in the industry and the company is known for their innovative microscopes and scientific instruments," continued Mr Barr. "We are excited to offer Leica surgical microscopes, as they enhance our ability to offer a ‘one-stop shop’ for an ophthalmic surgeons’ needs, while also accelerating the growth of our business.”

Eoghan O'Lionaird, president of Leica Microsystems, commented, "Through this partnership with Bausch + Lomb, we will be able to provide more patients around the world with better access to our world-leading imaging systems. We are pleased to have such a respected and innovative company as Bausch + Lomb as our partner. Our customers, their patients, and our business will benefit from this collaboration as ophthalmic surgeons will have a single source supplier for their equipment needs."

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.